Market Introduction
Allergen immunotherapy, also known as hypo-sensitization or desensitization, is a medical treatment for allergies. Measured doses of allergens are given to the patient resulting in reduced inflammation, which causes immune system to become less sensitive to the substance by blocking antibody function. Allergy immunotherapy primary therapeutic goals include reducing symptoms, reducing symptomatic medication use, and improving allergy-related quality of life.
Market Overview and Dynamics
The South and Central America Allergy immunotherapies market was valued at US$ 74.17 million in 2019 and is projected to reach US$ 154.88 million by 2027; it is expected to grow at a CAGR of 9.7% during the forecast period. The South and Central America allergy immunotherapies market is expected to grow owing to key driving factors such as the increasing prevalence of allergic disorders and technological advancements in sublingual dosage formulations. However, drawbacks associated with the use of allergy immunotherapies, restricted healthcare spending and regulatory variations across regions is likely to hamper the growth of the market during the forecast period.
Key Market Segments
The South and Central America Allergy immunotherapies market, based on treatment is segmented into Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT). In 2019, the Subcutaneous Immunotherapy (SCIT) segment held the largest share of the market, however, the Sublingual Immunotherapy (SLIT) segment is expected to grow at the fastest rate during the forecast period. Based on Allergy Type, the South and Central America allergy immunotherapies market was segmented into Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, and Others. The Allergic Rhinitis segment held the highest share of the Allergy immunotherapies market in 2019. Moreover, the same segment is anticipated to witness growth at a significant rate during the forecast period.
Based on distribution channel, the market is segmented into, hospital pharmacy, retail pharmacy and online pharmacy. In 2019, the hospital pharmacy settings segment held the largest share of the market and the same pharmacy segment is expected to grow at the fastest rate during the forecast period.
Major Sources and Companies Listed
Some of the major primary and secondary sources for South and Central America allergy immunotherapies market included in the report are Celsion Corporation; World Allergy Organization (WAO), World Health Organization (WHO); Latin American Society of Allergy, Asthma, and Immunology (SLAAI); and Argentine Association of Allergy and Clinical Immunology (AAAeIC).
Reasons to buy the report
- Determine prospective investment areas based on a detailed trend analysis of the South and Central America allergy immunotherapy market over the next years.
- Gain an in-depth understanding of the underlying factors driving demand for different South and Central America allergy immunotherapy segments in the top spending countries and identify the opportunities offered by each of them.
- Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
- Identify the major channels driving the South and Central America allergy immunotherapy market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
- Channelize resources by focusing on the ongoing programs undertaken by the different countries within the South and Central America immunotherapy market.
SOUTH AND CENTRAL AMERICA ALLERGY IMMUNOTHERAPIES MARKET SEGMENTATION
By Treatment
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
By Allergy Type
- Allergic Rhinitis
- Asthma
- Food Allergy
- Venom Allergy
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- Brazil
- Argentina
- Rest of South and Central America
Company Profiles
- HAL Allergy B.V.
- ALK Abello A/S
- Stallergenes Greer
- Anergis
- Circassia